Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells Journal Article


Authors: Wei, Y.; Chen, R.; Dimicoli, S.; Bueso-Ramos, C.; Neuberg, D.; Pierce, S.; Wang, H.; Yang, H.; Jia, Y.; Zheng, H.; Fang, Z.; Nguyen, M.; Ganan-Gomez, I.; Ebert, B.; Levine, R.; Kantarjian, H.; Garcia-Manero, G.
Article Title: Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells
Abstract: The molecular bases of myelodysplastic syndromes (MDS) are not fully understood. Trimethylated histone 3 lysine 4 (H3K4me3) is present in promoters of actively transcribed genes and has been shown to be involved in hematopoietic differentiation. We performed a genome-wide H3K4me3 CHIP-Seq (chromatin immunoprecipitation coupled with whole genome sequencing) analysis of primary MDS bone marrow (BM) CD34+ cells. This resulted in the identification of 36 genes marked by distinct higher levels of promoter H3K4me3 in MDS. A majority of these genes are involved in nuclear factor (NF)-κB activation and innate immunity signaling. We then analyzed expression of histone demethylases and observed significant overexpression of the JmjC-domain histone demethylase JMJD3 (KDM6b) in MDS CD34+ cells. Furthermore, we demonstrate that JMJD3 has a positive effect on transcription of multiple CHIP-Seq identified genes involved in NF-κB activation. Inhibition of JMJD3 using shRNA in primary BM MDS CD34+ cells resulted in an increased number of erythroid colonies in samples isolated from patients with lower-risk MDS. Taken together, these data indicate the deregulation of H3K4me3 and associated abnormal activation of innate immunity signals have a role in the pathogenesis of MDS and that targeting these signals may have potential therapeutic value in MDS. © 2013 Macmillan Publishers Limited.
Keywords: innate immunity; myelodysplastic syndromes; chip-seq; h3k4me3; jmjd3
Journal Title: Leukemia
Volume: 27
Issue: 11
ISSN: 0887-6924
Publisher: Nature Publishing Group  
Date Published: 2013-11-01
Start Page: 2177
End Page: 2186
Language: English
DOI: 10.1038/leu.2013.91
PROVIDER: scopus
PUBMED: 23538751
PMCID: PMC4476310
DOI/URL:
Notes: - Cited By (since 1996):2 - "Export Date: 2 December 2013" - "CODEN: LEUKE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ross Levine
    775 Levine